The Correlation between Serum Sclerostin Level and Arterial Stiffness in Peritoneal Dialysis Patients

Fang Liu,1,2 Hongbin Ma,3 Yongfeng Ma,4 Wei Zhou,5 Chenlu Wang,1 and Yongli Xiong 6

1Department of Kidney Diseases, Shexian Hospital of Traditional Chinese Medicine, Huangshan, Hebei, China
2Medical Department, Shexian Hospital of Traditional Chinese Medicine, Huangshan, Hebei, China
3Laboratory, Shexian Hospital of Traditional Chinese Medicine, Huangshan, Hebei, China
4Department of Radiology, Shexian Hospital of Traditional Chinese Medicine, Huangshan, Hebei, China
5Department of Function, Shexian Hospital of Traditional Chinese Medicine, Huangshan, Hebei, China
6Department of Science and Teach, Shexian Hospital of Traditional Chinese Medicine, Huangshan, Hebei, China

Correspondence should be addressed to Fang Liu; fangdiji06973@163.com

Received 25 May 2022; Revised 18 July 2022; Accepted 20 July 2022; Published 10 August 2022

Objective. To study the correlation between serum sclerostin (SO) and arterial stiffness in peritoneal dialysis (PD) patients.

Methods. The study included 50 Parkinson’s disease (PD) patients on continuous ambulatory peritoneal dialysis (CAPD) for more than 6 months at the nephrology department of our hospital. Without regard for age, the eligible patients were assigned to a low PWV group and a high PWV group with brachial-ankle pulse wave velocity (BaPWV) of 1400 cm/s as the cutoff value. Patient characteristics such as age, gender, height, weight, BMI, smoking history, dialysis age, systolic blood pressure (SBP), diastolic blood pressure (DBP), urea clearance index (Kt/V), residual renal function (RRF), and diabetes mellitus (DM) were analyzed. Biochemical indices for analysis include hemoglobin (Hb), albumin (ALB), total cholesterol (TC), urea nitrogen (BUN), creatinine (CREA), triglyceride (TG), uric acid (UA), parathyroid hormone (PTH), blood phosphorus (P), fasting blood glucose (GLU), correct calcium (Ca), calcium-phosphorus product, low-density lipoprotein (LDL-C), high-density lipoprotein (HDL-C), SO, and arterial stiffness. Results. There were 9 males and 16 females in the low PWV group and 12 males and 13 females in the high PWV group. Statistical significance was absent in patient characteristics despite more males in the high PWV group (P = 0.055). The low PWV group had significantly lower mean age, SBP, SO, and PWV level, fewer diabetic patients, and higher CREA than the control group. Analysis of PWV-related factors showed that PWV was positively correlated with age, P, Ca, GLU, SBP, PTH, and SO while negatively correlated with CREA. Multiple stepwise regression analysis showed that age, SO, and CREA demonstrated great potential to predict PWV (P < 0.05). Conclusion. The degree of vascular sclerosis is highly correlated with SO level in Parkinson’s disease patients, which might provide a theoretical basis for the evaluation of cardiovascular illness in Parkinson’s disease patients. High serum sclerostin level is a risk factor for deteriorated arterial stiffness. Given the limited sample size, the relevant results require further validation by expanding the sample size.

1. Introduction

The mortality rate of end-stage renal disease (ESRD) accounts for about 20% of all renal diseases, posing a great threat to the patients [1, 2]. The clinical efficacy of the two commonly used continuous renal replacement therapies (CRRTs), peritoneal dialysis (PD) and hemodialysis (HD), is similar [3]. PD patients are predisposed to complications such as calcium-phosphate metabolic disorders and bone lesions. Despite previous evidence on the varying magnitude of correlation between SO level and arterial stiffness, discrepancies result in compromised research outcomes [4, 5]. Research [6] showed that with prolonged dialysis, about 61.6% of peritoneal dialysis patients experienced abnormal digestive symptoms such as acid reflux, nausea and vomiting, early satiety, and postprandial bloating, leading to poor appetite and malnutrition in peritoneal dialysis patients. Medications such as acid suppressants and gastroprotective...
are frequently used in Western medicine, but the long-term efficacy is unfavorable. It has been shown [7] that traditional Chinese medicine (TCM) provides significant efficacy in the treatment of gastrointestinal dysfunction in peritoneal dialysis patients with fewer adverse effects. It was found that spleen deficiency is the main type of evidence in ESRD patients, and blood stasis and dampness are present throughout the disease. Patients with ESRD have a depleted kidney essence and require care to protect kidney qi to replenish the innate kidney essence [8].

The development of coronary heart disease is linked to systemic atherosclerosis. Patients with elevated levels of medial calcification may provide insight into this phenomenon, so it is feasible to assess the hypothesis of death and prognosis of patients [9–11]. Thus, accurate determination of the degree of AS in patients or exploration of related biomarkers is of great importance for patient prognosis [12]. Previous approaches for the detection of arterial elasticity included central aortic pressure (CAP), CT, ultrasound, and X-ray plain scanning, but all of them exhibit limitations. In recent years, arterial pulse wave velocity (PWV) has been widely used in the detection of arterial elasticity and achieved certain clinical results [13, 14]. It contributes to the early identification and prevention of vascular sclerotic illnesses by identifying arterial elasticity, vascular stiffness, and vascular stenosis [15, 16].

It has been found that dialysate calcium concentration is one of the important factors affecting calcium homeostasis in patients on maintenance hemodialysis, and dialysate higher than blood calcium concentration increases the risk of disorders of calcium and phosphorus metabolism in patients, leading to a variety of complications [17]. In peritoneal dialysis, the mode of calcium ion transport through the peritoneum in dialysate varies from that in maintenance hemodialysis, and the possibility that dialysate calcium concentration still yields a greater impact on calcium and phosphorus metabolism and bone metabolism in peritoneal dialysis patients deserves further in-depth study. To this end, this study investigated the incidence of cardiovascular events in individuals with typical Parkinson’s disease and documented alterations in serum sclerostin levels to evaluate the association between SO level and arterial stiffness in PD patients.

2. Materials and Methods

2.1. Research Subjects. 50 patients with PD on continuous ambulatory peritoneal dialysis (CAPD) for more than 6 months in the nephrology department of our hospital were included in the study.

Inclusion criteria were as follows: (1) patients meeting the criteria for dialysis in the Clinical Guidelines for Hemodialysis [18]; (2) duration of dialysis ≥3 months; (3) aged >18 years; (4) with complete data; (5) with regular PD ≥3 months; and (6) with acute physiological and chronic health status II scores [19] <25.

Exclusion criteria were as follows: (1) patients with mental illness or mobility difficulties that prevented cooperation with the study; (2) patients who used hormones or immunosuppressants within the past one year; (3) patients who underwent surgery or had trauma within the past one month; (4) patient with other serious diseases, such as malignant tumors; (5) patients with mental illnesses such as dementia and impaired consciousness; (6) patients with immune system disorders; (7) patients with severe liver function and cardiac insufficiency; (8) patients during pregnancy; (9) patients who revoked their consent or died; and (10) patients with renal failure requiring renal transplantation treatment. This study was approved by ethics committee of Shexian Hospital of Traditional Chinese Medicine, No.8293799/1, and our patients and their families signed informed consent.

2.2. Methods

(1) Collection of baseline patient profile, including age, gender, height, weight, BMI, smoking history, dialysis age, urea clearance index (Kt/V), residual renal function (RRF), diabetes mellitus (DM), diastolic blood pressure (DBP), and systolic blood pressure (SBP).

(2) Biochemical indicators, including hemoglobin (Hb), albumin (ALB), total cholesterol (TC), urea nitrogen (BUN), creatinine (CREA), triglyceride (TG), uric acid (UA), parathyroid hormone (PTH), blood phosphorus (P), fasting blood glucose (GLU), corrective calcium (Ca), calcium-phosphorus product, low-density lipoprotein (LDL-C), and high-density lipoprotein (HDL-C), were recorded.

(3) Detection of serum sclerostin concentration: the detection was performed with enzyme-linked immunosorbent assay (ELISA) double antibody sandwich method. 5 mL of fasting venous blood was collected from enrolled patients, and the supernatant was centrifuged and stored for testing. The levels of Hb, ALB, TC, BUN, CREA, TG, UA, PTH, GLU, Ca, LDL-C, HDL-C, BUN, P, Ca, and calcium and phosphorus were determined using a CX9 large automatic biochemical analyzer manufactured by Beckman Coulter, USA. The reagent kit was purchased from Tianjin Asil Biotechnology Co.

(4) Determination of arterial stiffness: each patient was given an arteriosclerosis detector to record their vascular stiffness measurement (baPWV). Without taking age into account, arterial stiffness (BaPWV) of 1400 cm/s was considered a cutoff value, with a value below 1400 cm/s considered normal. The mild elevation is defined as 20–30% over the usual value, moderate elevation is defined as 30%–50% above the normal value, and severe elevation is defined as more than 50% above the normal value.

2.3. Statistical Analysis. SPSS 24.0 was used for data processing in this study. The counting data and measurement data were analyzed using the chi-square (X^2) test and the t-test, respectively. Pearson linear correlation analysis was
used for correlation analysis between data. \( P < 0.05 \) indicates a statistically significant difference.

3. Results

3.1. Comparison of General Data of Patients in Two Groups. Without regard for age, the eligible patients were assigned to a low PWV group and a high PWV group with brachial-ankle pulse wave velocity (Ba PWV) of 1400 cm/s as the cutoff value. Statistical significance was absent in patient characteristics despite more males in the high PWV group \( (P = 0.055) \). The low PWV group had significantly lower mean age, SBP, SO, and PWV levels, fewer diabetic patients, and higher CREA than the control group (Table 1).

3.2. Analysis of PWV-Related Factors. PWV was shown to be correlated with age, SBP, PTH, P, Ca, and GLU, while negatively correlated with CREA (Table 2).

3.3. PWV Multiple Regression Analysis. Multiple stepwise regression analysis showed that age, SO, and SBP demonstrated great potential to predict PWV \( (P < 0.05) \) (Table 3).

4. Discussion

With the increasing incidence of chronic kidney disease, more than 100 million people in China are suffering from chronic kidney disease, and a significant proportion of these patients have progressed to the end stage and require renal replacement therapy. Peritoneal dialysis is the main alternative therapy for patients with end-stage renal disease in China due to its simple operation, no site restrictions, and its advantages over hemodialysis in protecting patients’ residual renal function and maintaining hemodynamic stability [20–22]. With the increase in the number of patients on peritoneal dialysis and the prolongation of patients’ dialysis, patients’ quality of life and dialysis efficacy have gradually been highlighted, and the factors affecting patients’ quality of life and dialysis efficacy mainly include residual renal function, nutritional status, peritonitis, peritoneal function, and other related complications [23]. Many clinical studies have confirmed [24, 25] that TCM carries great significance in the prevention and treatment of dialysis-related complications in peritoneal dialysis patients and in improving the efficacy of treatment. ESRD belongs to the category of “edema” and “deficiency labor” in TCM, and spleen deficiency is considered the main type of evidence in ESRD patients, and blood stasis and dampness are present throughout the disease. Patients with ESRD have a depleted kidney essence and require care to protect kidney qi to replenish the innate kidney essence [26].

Sclerostin, a glycoprotein expressed by the SOST gene in osteocytes, is a newly identified protein implicated in bone-vascular axis metabolism and is hypothesized to be related to the development of arteriosclerosis and vascular calcification [27]. Sclerostin is a newly identified protein that regulates vascular calcification and has been found in calcified vascular smooth muscle cells in addition to bone-derived sclerostin [28, 29]. Studies have shown that serum sclerostin levels gradually increase with the progression of CKD, and the relevant mechanism is unclear [30, 31]. Increased cardiovascular and cerebrovascular events in patients with chronic kidney disease (CKD) may be associated with arteriosclerosis, and PWV, as an index of arterial stiffness, contributes to non-invasively diagnosing the severity of vascular sclerosis [32, 33]. Studies have shown that baPWV is a strong predictor of cardiovascular mortality in HD patients, and SO level may serve as a potential biomarker of atherosclerosis, whereas there is a dearth of relevant research. At present, non-invasive methods for PWV measurement based on waveform analysis include brachial-ankle pulse wave velocity (baPWV), heart rate, and multi-neck pulse wave (cfPWV), among which cfPWV directly reflects the degree of aortic stiffness and shows excellent clinical relevance. It is currently considered the gold standard for assessing aortic stiffness and cardiovascular events [34, 35]. Recent research has shown that hyperphosphatemia, high calcium-phosphorus product, and hyperparathyroidism could lead to vascular calcification, increased arterial stiffness, and an increased risk of cardiovascular events [36].

The analysis of PWV-related factors in the present study showed that PWV was positively correlated with age, SBP, PTH, SO, P, Ca, and GLU while negatively related with CREA. The results of multiple stepwise regression analysis indicated that the age, SBP, and SO were predictors of PWV \( (P < 0.05) \). SO level in PD patients is significantly related with vascular sclerosis severity, which provides a theoretical basis for the evaluation of cardiovascular disease in PD patients. The level of PWV in PD patients was correlated with age, BNP, brachial artery systolic blood pressure, Hb, and previous history of DM. It is indicated that the control of blood pressure, volume, and blood glucose is key to achieve vascular function protection.

This may be related to the small sample size of this study and possibly because this study did not group patients with or without other preexisting diseases. It has been suggested that hemodialysis corrects disorders of calcium and phosphorus metabolism, improves vascular calcification and arterial stiffness, and delays or blocks arterial calcification and sclerosis in patients with abnormal parathyroid function [37]. Active vitamin D deficiency is prevalent in peritoneal dialysis patients. Krause et al. [38] found that 58.8% of maintenance hemodialysis patients had 25-hydroxyvitamin D deficiency and that vitamin D deficiency increased mortality. Therefore, specific correlations are required in animal experiments.

The degree of vascular sclerosis is highly correlated with SO level in Parkinson’s disease patients, which might provide a theoretical basis for the evaluation of cardiovascular illness in Parkinson’s disease patients. High serum sclerostin
level is a risk factor for deteriorated arterial stiffness. Given the limited sample size, the relevant results require further validation by expanding the sample size.

Table 1: Comparison of general data of patients in two groups.

| Factor                        | Low PWV group (n = 25) | High PWV group (n = 25) | P     |
|-------------------------------|------------------------|-------------------------|-------|
| Age                           | 56.23 ± 13.24          | 65.43 ± 8.81            | <0.001|
| Gender (male/female)          | 9/16                   | 12/13                   | 0.055 |
| Height                        | 158.01 ± 7.73          | 161.37 ± 7.49           | 0.314 |
| Weight                        | 59.38 ± 11.26          | 60.47 ± 10.63           | 0.658 |
| BMI                           | 23.57 ± 4.49           | 23.90 ± 3.61            | 0.621 |
| Smoking                       | 14                     | 17                      | 1.233 |
| Dialysis time                 | 30.31 ± 26.17          | 24.47 ± 15.31           | 0.131 |
| Urea clearance index (Kt/V)   | 1.55 ± 0.54            | 1.67 ± 0.75             | 0.762 |
| Residual renal function (RRF) | 0.57 ± 0.63            | 0.59 ± 0.62             | 0.652 |
| Systolic blood pressure (SBP) | 134.34 ± 22.45         | 158.72 ± 22.36          | 0.006 |
| Diastolic blood pressure (DBP)| 83.76 ± 13.84          | 83.51 ± 14.27           | 0.112 |
| Diabetes mellitus             | 2                      | 8                       | <0.001|
| Hemoglobin (Hb)               | 114.67 ± 21.51         | 116.53 ± 18.74          | 0.591 |
| Albumin (ALB)                 | 37.39 ± 4.28           | 36.27 ± 3.64            | 0.138 |
| Blood urea nitrogen (BUN)     | 23.15 ± 5.53           | 21.16 ± 5.62            | 0.145 |
| Creatinine (CREA)             | 881.33 ± 247.83        | 742.41 ± 272.63         | 0.003 |
| Uric acid (UA)                | 383.25 ± 93.69         | 404.92 ± 91.31          | 0.225 |
| Parathyroid hormone (PTH)     | 2.09 ± 0.51            | 1.95 ± 0.49             | 0.775 |
| Serum phosphorus (P)          | 1.66 ± 0.37            | 1.57 ± 0.35             | 0.104 |
| Corrected calcium (Ca)        | 2.23 ± 0.32            | 2.21 ± 0.27             | 0.846 |
| Calcium-phosphorus product    | 3.42 ± 1.43            | 3.38 ± 1.27             | 0.936 |
| Total cholesterol (TC)        | 4.68 ± 1.02            | 5.03 ± 1.25             | 0.232 |
| Triglyceride (TG)             | 2.03 ± 1.26            | 2.09 ± 1.28             | 0.832 |
| Low-density lipoprotein (LDL-C)| 3.15 ± 0.73            | 1.46 ± 0.97             | 0.42  |
| High-density lipoprotein (HDL-C)| 1.33 ± 0.35         | 1.44 ± 0.93             | 0.547 |
| Fasting blood sugar (GLU)     | 5.63 ± 1.67            | 6.37 ± 2.56             | 0.083 |
| Serum sclerostin              | 202.13 ± 20.14         | 433.37 ± 24.32          | 0.004 |
| PWV                           | 9.66 ± 1.35            | 13.36 ± 1.48            | <0.001|

Data Availability

No data were used to support this study.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This study was supported by the Hebei Provincial Health Commission Scientific Research Project (20201331).

References

[1] S. Ahmadmehrabi and W. H. W. Tang, “Hemodialysis-induced cardiovascular disease,” Seminars in Dialysis, vol. 31, no. 3, pp. 258–267, 2018.
[2] A. Chuasawan, S. Pooripussarakul, A. Thakkinstant, A. Ingsathit, and O. Pattanaprateep, “Comparisons of quality of life between patients underwent peritoneal dialysis and hemodialysis: a systematic review and meta-analysis,” Health and Quality of Life Outcomes, vol. 18, no. 1, p. 191, 2020.
[3] M. Cozzolino, M. Mangano, A. Stucchi, P. Ciceri, F. Conte, and A. Galassi, “Cardiovascular disease in dialysis patients,” Nephrology Dialysis Transplantation, vol. 33, no. 3, pp. iii28–iii34, 2018.
[4] C. Garofalo, S. Borrelli, T. De Stefano et al., “Incremental dialysis in ESRD: systematic review and meta-analysis,” Journal of Nephrology, vol. 32, no. 5, pp. 823–836, 2019.
Evidence-Based Complementary and Alternative Medicine

[5] H. Kanda, Y. Hirasaki, T. Iida et al., "Perioperative management of patients with end-stage renal disease," Journal of Cardiothoracic and Vascular Anesthesia, vol. 31, no. 6, pp. 2251–2267, 2017.

[6] J. F. Shen, L. W. Hu, and F. Hu, "Efficacy of renal failure formula combined with Western medicine in the treatment of maintenance peritoneal dialysis patients," Chinese Journal of Traditional Chinese Medicine, vol. 36, no. 05, pp. 3030–3033, 2021.

[7] Y. B. Shuang and Y. Wen, "The efficacy of the formula to benefit the kidney and invigorate blood on peritoneal dialysis. The effect of the formula for benefiting kidney and activating blood on residual kidney function in peritoneal dialysis patients," Shaanxi TCM, vol. 42, no. 04, pp. 486–488, 2021.

[8] B. Yang, M. Wang, Meng, and L. Sun, "Effects of Fu Ren Formula on peritoneal function and VEGF, TNF-α, IL-12 and IFN-γ in uremic peritoneal dialysis rats," Chinese Journal of Comparative Medicine, vol. 31, no. 04, pp. 15–20, 2021.

[9] E. Lam, Y. T. K. Lien, W. K. Kraft et al., "Vancomycin in peritoneal dialysis: clinical pharmacology considerations in therapy," Peritoneal Dialysis International, vol. 40, no. 4, pp. 384–393, 2020.

[10] T. Li, C. Wilcox, M. Lipkowitz, J. Gordon-Cappitelli, and S. Dragoi, "Rationale and strategies for preserving residual kidney function in dialysis patients," American Journal of Nephrology, vol. 50, no. 06, pp. 411–421, 2019.

[11] B. Mehdi, H. Kaveh, and V. F. Ali, "Implantable cardioverter-defibrillators in patients with ESRD: complications, management, and literature review," Current Cardiology Reviews, vol. 15, no. 03, pp. 161–166, 2019.

[12] Y. Miyata, Y. Obata, Y. Mochizuki et al., "Periodontal disease in patients receiving dialysis," International Journal of Molecular Sciences, vol. 20, no. 15, p. 3805, 2019.

[13] B. S. Park, M. Seong, J. Ko et al., "Differences of connectivity between ESRD patients with PD and HD," Brain Behav, vol. 10, no. 08, Article ID e01708, 2020.

[14] G. Fiori, F. Fuiano, A. Scorzà, S. Conforto, and S. A. Scuito, "Non-invasive methods for PWV measurement in blood vessel stiffness assessment," IEEE Rev Biomed Eng, vol. 15, pp. 169–183, 2022.

[15] H. Moradi, E. Streja, and N. D. Vaziri, "ESRD-induced dyslipidemia-Should management of lipid disorders differ in dialysis patients?" Seminars in Dialysis, vol. 31, no. 04, pp. 398–405, 2018.

[16] L. Nardelli, A. Scalamogna, M. Gallieni, E. Favi, P. Messa, and G. Castellano, "Urgent-start PD: a viable approach," Giornale Italiano di Nefrologia, vol. 38, no. 06, 2021.

[17] Q. Zhu, J. W. Han, and L. Y. Wu, "Effect of low-calcium hemodialysis and low-calcium peritoneal dialysis on calcium and phosphorus metabolism and carotid artery calcification in uremic patients," Chinese Journal of Physicians, vol. 24, no. 04, pp. 598–600, 2022.

[18] L. H. Yang, W. Jin, and Z. Q. Ruan, "Clinical hemodialysis online blood volume monitoring with dry weight adjustment and care," Zhejiang Medicine, vol. 36, no. 09, pp. 821–823, 2014.

[19] Z. An, D. Wang, and J. Zhu, "Acute physiology and chronic health status scoring system II and nutritional risk screening-2002 in critically ill patients," Chinese Journal of Clinical Health Care, vol. 17, no. 06, pp. 570–573, 2014.

[20] X. J. Wang, Observation on the Effect of Fu Ren Fang on Dialysis Adequacy in Long-Term Abdominal Dialysis Patients: 2016 Annual Meeting of the Renal Disease Committee of the Chinese Society of Integrative Medicine, 2016.

[21] H. Zhang, C. Liu, and Q. Li, "Study on the effect of yielding kidney, removing blood stasis and reducing turbidity formula on TGF-β1/smad signaling pathway in renal fibrosis in peritoneal dialysis patients," Journal of Modern Traditional Chinese and Western Medicine, vol. 28, no. 32, pp. 3545–3548, 2019.

[22] L. Jiao and Y. Deng, "Clinical observation on the intervention of the formula of strengthening the spleen, benefitting the kidney and activating blood in patients on maintenance peritoneal dialysis," Chinese Journal of Integrated Chinese and Western Medicine and Nephrology, vol. 19, no. 10, pp. 889–891, 2018.

[23] L. F. Meng, X. C. Chun, and Z. H. Tao, Clinical Study on Antagonizing Peritoneal Fibrosis in Peritoneal Dialysis Patients by Strengthening the Spleen, Removing Phlegm and Eliminating Sāsā, 2014.

[24] Y. B. Suo and C. Chen, Observation on the Efficacy of Yi Qi and Jian Spleen Formula on Malnutrition in Maintenance Peritoneal Dialysis Patients: 2018 Annual Meeting of the Renal Disease Committee of the Chinese Society of Integrative Medicine, 2018.

[25] F. Meng, W. Shi, and J. M. Fan, Study on the Effect and Mechanism of Jiānshuānyi Jī Formula to Improve Peritoneal Injury Induced by Microinflammatory State in Rats on Peritoneal Dialysis: 2018 Annual Meeting of the Renal Diseases Committee of the Chinese Society of Integrative Medicine, 2018.

[26] S. Du, Study on the Mechanism of Regulating mTOR Signaling Pathway to Prevent Peritoneal Fibrosis in PD Rats Based on the Principle of the Spleen Dominates the Abdomen, Guangxi University of Traditional Chinese Medicine, Nanning, China, 2018.

[27] A. Catalano, F. Bellone, N. Morabito, and F. Corica, "Sclerostin and vascular pathophysiology," International Journal of Molecular Sciences, vol. 21, no. 13, p. 4779, 2020.

[28] B. L. Langdahl, L. C. Hofbauer, and J. C. Forfar, "Cardiovascular safety and sclerostin inhibition," Journal of Clinical Endocrinology and Metabolism, vol. 106, no. 07, pp. 1845–1853, 2021.

[29] J. S. Wang, C. M. Mazur, and M. N. Wein, "Sclerostin and osteocalcin: candidate bone-produced hormones," Frontiers in Endocrinology, vol. 12, Article ID 584147, 2021.

[30] A. C. Reaves and D. E. Weiner, "The ESRD quality incentive program: everything can be improved," American Journal of Kidney Diseases, vol. 78, no. 06, pp. 907–910, 2020.

[31] A. Sabatino, G. Piotti, C. Cosola, I. Gandolfini, J. Kooman, and E. Fiaccadori, "Dietary protein and nutritional supplements in conventional hemodialysis," Seminars in Dialysis, vol. 31, no. 06, pp. 583–591, 2018.

[32] M. Salani, S. Roy, and W. H. t. Fissell, "Innovations in vascular safety and sclerostin inhibition," Journal of Clinical Endocrinology and Metabolism, vol. 106, no. 07, pp. 1845–1853, 2021.
[35] K. Dumor, M. Shoemaker-Moyle, R. Nistala, and A. WhaleyConnell, "Arterial stiffness in hypertension: an update," Current Hypertension Reports, vol. 20, no. 8, p. 72, 2018.

[36] Y. Liu, C. Zeng, and S. Tang, "Analysis of factors influencing calcium and phosphorus metabolism in peritoneal dialysis patients," China Medical Journal, vol. 57, no. 06, pp. 626–630, 2022.

[37] C. Fortier, F. Mac-Way, S. A. De Serres et al., "Active vitamin D and accelerated progression of aortic stiffness in hemodialysis patients: a longitudinal observational study," American Journal of Hypertension, vol. 27, no. 11, pp. 1346–1354, 2014.

[38] R. Krause, H. J. Schober-Halstenberg, G. Edenharter, K. Haas, H. J. Roth, and U. Frei, "Vitamin D status and mortality of German hemodialysis patients," Anticancer Research, vol. 32, no. 1, pp. 391–395, 2012.